Sequential treatment with intermittent low-dose human parathyroid hormone (1-34) and bisphosphonate enhances large-size skeletal reconstruction by vascularized bone transplantation

Calcified Tissue International

Volumn 81, Issue 3, 2007, Pages 232-239

  Hashimoto, Takahiro ^a   Shigetomi, Mitsunori ^a   Ohno, Teruyasu ^a   Matsunaga, Tsunemitsu ^a   Muramatsu, Keiichi ^a   Tanaka, Hiroshi ^a   Sugiyama, Toshihiro ^a,b   Taguchi, Toshihiko ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Bisphosphonate; Parathyroid hormone; Sequential treatment; Skeletal reconstruction; Vascularized bone transplantation

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE GRAFT; BONE MASS; BONE REMODELING; BONE STRENGTH; BONE TRANSPLANTATION; CALLUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; FEMUR; FRACTURE; LOW DRUG DOSE; MALE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SKELETON; SKELETON MALFORMATION; TIBIA; TREATMENT DURATION; VASCULARIZATION;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE TRANSPLANTATION; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FRACTURE HEALING; FRACTURES, BONE; HUMANS; MALE; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED LEW;

EID: 34548486474     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-007-9056-7     Document Type: Article

References (50)

1. Taylor GI, Miller GD, Ham FJ (1975) The free vascularized bone graft: a clinical extension of microvascular techniques. Plast Reconstr Surg 55:533-544
2. Doi K, Kawai S, Shigetomi M (1996) Congenital tibial pseudoarthrosis treated with vascularised bone allograft. Lancet 347:970-971
3. Wood MB (2007) Free vascularized fibular grafting-25 years' experience: tips, techniques, and pearls. Orthop Clin North Am 38:1-12
4. Bishop AT, Pelzer M (2007) Vascularized bone allotransplantation: current state and implications for future reconstructive surgery. Orthop Clin North Am 38:109-122
5. Aspenberg P (2005) Drugs and fracture repair. Acta Orthop 76:741-748
6. Simpson AHRW, Mills L, Noble B (2006) The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br 88:701-705
7. William Axelrad T, Kakar S, Einhorn TA (2007) New technologies for the enhancement of skeletal repair. Injury 38(suppl 1):S49-S62
8. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM, Darby AJ, Tregear GW, Parsons JA (1976) Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1:1035-1038
9. Reeve J (2002) Recombinant human parathyroid hormone: osteoporosis is proving amenable to treatment. BMJ 324:435-436
10. Tashjian AH Jr, Gagel RF (2006) Teriparatide [human PTH (1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21:354-365
11. Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960-968
12. Holzer G, Majeska RJ, Lundy MW, Hartke JR, Einhorn TA (1999) Parathyroid hormone enhances fracture healing: a preliminary report. Clin Orthop Relat Res 366:258-263
13. Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Yamazaki M (2002) Mechanisms of the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17:2038-2047
14. Andreassen TT, Willick GE, Morley P, Whitfield JF (2004) Treatment of parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 74:351-356
15. Komatsubara S, Mori S, Mashiba T, Nonaka K, Seki A, Akiyama T, Miyamoto K, Cao Y, Manabe T, Norimatsu H (2005) Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 36:678-687
16. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA (2005) Enhancement of experimental fracture-healing by systemic administration of recombination human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87:731-741
17. Seebach C, Skripitz R, Andreassen TT, Aspenberg P (2004) Intermittent parathyroid hormone (1-34) enhances mechanical strength and density of new bone after distraction osteogenesis in rats. J Orthop Res 22:472-478
18. Skripitz R, Bohling S, Ruther W, Aspenberg P (2005) Stimulation of implant fixation by parathyroid hormone (1-34): a histomorphometric comparison of PMMA cement and stainless steel. J Orthop Res 23:1266-1270
19. Gabet Y, Muller R, Levy J, Dimarchi R, Chorev M, Bab I, Kohavi D (2006) Parathyroid hormone 1-34 enhances titanium implant anchorage in low-density trabecular bone: a correlative micro-computed tomographic and biomechanical analysis. Bone 39:276-282
20. Gunness-Hey M, Hock JM (1989) Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone 10:447-452
21. Ejersted C, Oxlund H, Eriksen EF, Andreassen TT (1998) Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone 23:43-52
22. Ejersted C, Oxlund H, Andreassen TT (1998) Bisphosphonate maintains parathyroid hormone (1-34)-induced cortical bone mass and mechanical strength in old rats. Calcif Tissue Int 62:316-322
23. Rhee Y, Won Y-Y, Baek M-H, Lim S-K (2004) Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats. J Bone Miner Res 19:931-937
24. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703
25. Cranney A, Papanioannou A, Zytaruk N, Hanley D, Adachi J, Goltzman D, Murray T, Hodsman A, for the Clinical Guidelines Committee of Osteoporosis Canada (2006) Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 175:52-59
26. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
27. Hornby SB, Evans GP, Hornby SL, Pataki A, Glatt M, Green JR (2003) Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int 72:519-527
28. Glatt M, Pataki A, Evans GP, Hornby SB, Green JR (2004) Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 15:707-715
29. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW (2006) Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239-248
30. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, for the HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
31. Shigetomi M, Doi K, Kuwata N, Muramatsu K, Yamamoto K, Kawai S (1994) Experimental study on vascularized bone allografts for reconstruction of massive bone defects. Microsurgery 15:663-670
32. 3, on bone reconstruction by vascularized bone allograft. Bone 30:422-427
33. Ohno T, Shigetomi M, Ihara K, Matsunaga T, Hashimoto T, Kawano H, Sugiyama T, Kawai S (2003) Skeletal reconstruction by vascularized allogenic bone transplantation: effects of statin in rats. Transplantation 76:869-871
34. Tsubone T, Shigetomi M, Ihara K, Ikeda K, Merida L, Ohno T, Sugiyama T, Kawai S (2003) Hypertrophy of vascularized bone isograft in rats treated with cyclosporine A. Calcif Tissue Int 73:393-399
35. Ikeda K, Shigetomi M, Ihara K, Tsubone T, Hashimoto T, Kawano H, Sugiyama T, Kawai S (2004) Effects of cessation of immunosuppression on skeleton reconstructed by vascularized bone allograft in rats. J Orthop Res 22:388-394
36. Oxlund H, Ortoft G, Thomsen JS, Danielsen CC, Ejersted C, Andreassen TT (2006) The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 39:244-252
37. Nakazawa T, Nakajima A, Shinomi K, Moriya H, Einhorn TA, Yamazaki M (2005) Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 37:711-719
38. Mori S (2003) Fracture healing with anti-resorptive agents. J Musculoskelet Neuronal Interact 3:314-316
39. Morris CD, Einhorn TA (2005) Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am 87:1609-1618
40. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301
41. Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355:2048-2050
42. Li J, Mori S, Kaji Y, Kawanishi J, Akiyama T, Norimatsu H (2000) Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15:2042-2051
43. Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 14:969-979
44. Li CY, Mori S, Li JL, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16:429-436
45. Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237-2246
46. Matsunaga T, Shigetomi M, Hashimoto T, Suzuki H, Gondo T, Tanaka H, Sugiyama T, Taguchi T (2007) Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats. Osteoporos Int. doi:10.1007/s00198-007-0387-z
47. Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, Seki A, Sun Y-X, Yamamoto T (2007) Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 40:1475-1482
48. Chalidis B, Tzioupis C, Tsiridis E, Giannoudis PV (2007) Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications. Expert Opin Investig Drugs 16:441-449
49. Civitelli R, Napoli N, Armamento-Villareal R (2007) Use of intravenous bisphosphonates in osteoporosis. Curr Osteoporos Rep 5:8-13
50. Compston J (2007) Treatments for osteoporosis: looking beyond the HORIZON. N Engl J Med 356:1878-1880